Skip to content

Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Non-small Cell Lung Cancer

Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Non-small Cell Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015762
Enrollment
Unknown
Registered
2018-04-19
Start date
2018-05-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Gold Standard:A biopsy or surgical excision of a tissue specimen from a lung occupying lesion or a lung metastatic lesion is diagnosed by histopathologic and/or cytological examination as non-small ce
in&#32
the&#32
a&#32
model&#32
and&#32
were&#32
by&#32

Sponsors

The Fifth Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Case inclusion criteria: 1. Diagnosis of non-small cell lung cancer according to pathological diagnostic criteria or clinical diagnostic criteria; 2. Enhanced display of tumor volume (> 1 cm) by CT or MRI contrast agents or pulmonary masses confirmed by arteriography; 3. for considering the existence of distant metastasis, tumor patients, metastases to the torso need CT examination confirmed that bone metastases should be confirmed by the whole body bone scan, there need to be confirmed by MRI brain metastases tumor metastases to the typical imaging features of the mass; 4. Older than 18 years, less than 65 years old, no gender restrictions; 5. Patients who have not undergone surgery, interventional therapy, chemotherapy, biological therapy and radiotherapy. 6. general condition score ECOG: 0-2; Dysfunction of main organs; Oxygen partial pressure is greater than 10.64kPa; The white cells are greater than or equal to 4 times 10^9/L; Blood routine hemoglobin is greater than 9.5g/dL; The absolute number of neutrophils is greater than or equal to 1.5 * 10^9/L; Platelet count is greater than 100 x 10^9/L; Total bilirubin was no more than 1.5 times normal value; Creatinine is no more than 1.25 times normal; Creatinine clearance rate is greater than 60ml/min; 7. Can obtain complete follow-up information, understand the situation of this study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Poor control of diabetic patients(fasting blood-glucose> 200 mg/dL); 2. in addition to the in situ squamous cell skin cancer, cervical cancer, basal or intraductal carcinoma in situ (mammary gland), organ localized prostate cancer 4 kinds of feasible radical resection of malignant tumor, with any other malignant tumours within five years; 3. breastfeeding and/or pregnant women; 4. Patients with severe bleeding tendency (less than 50% of thrombin time and cannot be corrected by vitamin K treatment); 5. Recent severe hemoptysis, severe cough, dyspnea or inability to cooperate with patients; 6. Severe emphysema, pulmonary congestion, and pulmonary heart disease; 7. The researchers believe that the subject may not be able to complete this study or may not comply with the requirements of this study (for reasons of management or other reasons).

Design outcomes

Primary

MeasureTime frame
Two-compartment four-parameter model (2TCM);Patlak two-parameter model;

Countries

China

Contacts

Public ContactHong-Jun Jin

The Fifth Affiliated Hospital of Sun Yat-sen University

jinhj3@mail.sysu.edu.cn+86 13823061907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026